Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Technical Development of a New Meningococcal Conjugate Vaccine.

Frasch CE, Kapre SV, Lee CH, Préaud JM.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S404-9. doi: 10.1093/cid/civ595. Review.

2.

Description and nomenclature of Neisseria meningitidis capsule locus.

Harrison OB, Claus H, Jiang Y, Bennett JS, Bratcher HB, Jolley KA, Corton C, Care R, Poolman JT, Zollinger WD, Frasch CE, Stephens DS, Feavers I, Frosch M, Parkhill J, Vogel U, Quail MA, Bentley SD, Maiden MC.

Emerg Infect Dis. 2013 Apr;19(4):566-73. doi: 10.3201/eid1904.111799.

3.

Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM).

Frasch CE, Preziosi MP, LaForce FM.

Hum Vaccin Immunother. 2012 Jun;8(6):715-24. doi: 10.4161/hv.19619. Epub 2012 Apr 12. Review.

PMID:
22495119
4.

Capsular serotype of Staphylococcus aureus in the era of community-acquired MRSA.

Sutter DE, Summers AM, Keys CE, Taylor KL, Frasch CE, Braun LE, Fattom AI, Bash MC.

FEMS Immunol Med Microbiol. 2011 Oct;63(1):16-24. doi: 10.1111/j.1574-695X.2011.00822.x. Epub 2011 Jul 18.

5.

Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines.

Poolman J, Frasch C, Nurkka A, Käyhty H, Biemans R, Schuerman L.

Clin Vaccine Immunol. 2011 Feb;18(2):327-36. doi: 10.1128/CVI.00402-10. Epub 2010 Dec 1.

6.

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines.

Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, Moxon ER, Stella M, Comanducci M, Bambini S, Muzzi A, Andrews W, Chen J, Santos G, Santini L, Boucher P, Serruto D, Pizza M, Rappuoli R, Giuliani MM.

Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19490-5. doi: 10.1073/pnas.1013758107. Epub 2010 Oct 20.

7.

Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines.

Poolman JT, Frasch CE, Käyhty H, Lestrate P, Madhi SA, Henckaerts I.

Clin Vaccine Immunol. 2010 Jan;17(1):134-42. doi: 10.1128/CVI.00289-09. Epub 2009 Nov 4.

8.

Preparation of bacterial polysaccharide-protein conjugates: analytical and manufacturing challenges.

Frasch CE.

Vaccine. 2009 Oct 30;27(46):6468-70. doi: 10.1016/j.vaccine.2009.06.013. Epub 2009 Jun 24. Review.

PMID:
19555714
9.

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease.

Frasch CE, Borrow R, Donnelly J.

Vaccine. 2009 Jun 24;27 Suppl 2:B112-6. doi: 10.1016/j.vaccine.2009.04.065. Epub 2009 May 21. Review.

PMID:
19464093
10.

Clinical characteristics of a novel 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine candidate (PHiD-CV). Introduction.

Dagan R, Frasch C.

Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S63-5. doi: 10.1097/INF.0b013e318199f5f2. No abstract available.

PMID:
19325448
11.

Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa.

Lee CH, Kuo WC, Beri S, Kapre S, Joshi JS, Bouveret N, LaForce FM, Frasch CE.

Vaccine. 2009 Jan 29;27(5):726-32. doi: 10.1016/j.vaccine.2008.11.065. Epub 2008 Dec 6.

PMID:
19063929
12.
13.

Characterization and immunogenicity of meningococcal group C conjugate vaccine prepared using hydrazide-activated tetanus toxoid.

Silveira IA, Bastos RC, Neto MS, Laranjeira AP, Assis EF, Fernandes SA, Leal ML, Silva WC, Lee CH, Frasch CE, Peralta JM, Jessouroun E.

Vaccine. 2007 Oct 10;25(41):7261-70. Epub 2007 Aug 7.

PMID:
17719147
14.

Differential capacities of outer membrane proteins from Neisseria meningitidis B to prime the murine immune system after vaccination.

Silva Junior FC, Gioia CA, Oliveira JM, Cruz SC, Frasch CE, Milagres LG.

Scand J Immunol. 2007 Jan;65(1):1-7.

15.

Phylogenetic lineages of invasive and colonizing strains of serotype III group B Streptococci from neonates: a multicenter prospective study.

Lin FY, Whiting A, Adderson E, Takahashi S, Dunn DM, Weiss R, Azimi PH, Philips JB 3rd, Weisman LE, Regan J, Clark P, Rhoads GG, Frasch CE, Troendle J, Moyer P, Bohnsack JF.

J Clin Microbiol. 2006 Apr;44(4):1257-61.

16.

Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines.

Romero-Steiner S, Frasch CE, Carlone G, Fleck RA, Goldblatt D, Nahm MH.

Clin Vaccine Immunol. 2006 Feb;13(2):165-9. Review. No abstract available.

17.

Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.

Rapoport AP, Stadtmauer EA, Aqui N, Badros A, Cotte J, Chrisley L, Veloso E, Zheng Z, Westphal S, Mair R, Chi N, Ratterree B, Pochran MF, Natt S, Hinkle J, Sickles C, Sohal A, Ruehle K, Lynch C, Zhang L, Porter DL, Luger S, Guo C, Fang HB, Blackwelder W, Hankey K, Mann D, Edelman R, Frasch C, Levine BL, Cross A, June CH.

Nat Med. 2005 Nov;11(11):1230-7. Epub 2005 Oct 16.

PMID:
16227990
18.

Effect of a booster dose of serogroup B meningococcal vaccine on antibody response to Neisseria meningitidis in mice vaccinated with different immunization schedules.

Gioia CA, de Sousa AB, Cruz SC, Junior FC, Andrade AF, Sassi RM, Frasch CE, Milagres LG.

FEMS Immunol Med Microbiol. 2005 Apr 1;44(1):35-42.

19.

Recent developments in Neisseria meningitidis group A conjugate vaccines.

Frasch CE.

Expert Opin Biol Ther. 2005 Feb;5(2):273-80. Review.

PMID:
15757388
20.

Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations.

Mikolajczyk MG, Concepcion NF, Wang T, Frazier D, Golding B, Frasch CE, Scott DE.

Clin Diagn Lab Immunol. 2004 Nov;11(6):1158-64.

21.

Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen.

Lin FY, Weisman LE, Azimi PH, Philips JB 3rd, Clark P, Regan J, Rhoads GG, Frasch CE, Gray BM, Troendle J, Brenner RA, Moyer P, Clemens JD.

J Infect Dis. 2004 Sep 1;190(5):928-34. Epub 2004 Jul 28.

PMID:
15295698
22.

Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock.

Jessouroun E, da Silveira IF, Larangeira AP, Pereira S, Fernandes SA, Rabinovitch L, Frasch CE, Castro-Faria-Neto HC, Bozza PT.

Vaccine. 2004 Jun 30;22(20):2617-25.

PMID:
15193387
23.

Protective immunity of pneumococcal glycoconjugates.

Lee CJ, Lee LH, Frasch CE.

Crit Rev Microbiol. 2003;29(4):333-49. Review.

PMID:
14636043
24.

Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae.

Romero-Steiner S, Frasch C, Concepcion N, Goldblatt D, Käyhty H, Väkeväinen M, Laferriere C, Wauters D, Nahm MH, Schinsky MF, Plikaytis BD, Carlone GM.

Clin Diagn Lab Immunol. 2003 Nov;10(6):1019-24.

25.

Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.

Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, Plikaytis B, Benjamin W, Quataert SA, Hildreth S, Sikkema DJ, Käyhty H, Jonsdottir I, Nahm MH.

Clin Diagn Lab Immunol. 2003 Jul;10(4):514-9. Review. No abstract available.

26.

Correlates of immunity for pneumococcal conjugate vaccines.

Lee LH, Frasch CE, Falk LA, Klein DL, Deal CD.

Vaccine. 2003 May 16;21(17-18):2190-6. Review.

PMID:
12706710
27.

High burden of invasive Streptococcus agalactiae disease in South African infants.

Madhi SA, Radebe K, Crewe-Brown H, Frasch CE, Arakere G, Mokhachane M, Kimura A.

Ann Trop Paediatr. 2003 Mar;23(1):15-23.

PMID:
12648320
28.

Immune response to native NadA from Neisseria meningitidis and its expression in clinical isolates in Brazil.

Fukasawa LO, Gorla MC, Lemos AP, Schenkman RP, Brandileone MC, Fox JW, Raw I, Frasch CE, Tanizaki MM.

J Med Microbiol. 2003 Feb;52(Pt 2):121-5.

PMID:
12543917
29.
30.
31.

Development and evaluation of pneumococcal conjugate vaccines: clinical trials and control tests.

Lee LH, Lee CJ, Frasch CE.

Crit Rev Microbiol. 2002;28(1):27-41. Review.

PMID:
12003039
32.

Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study.

Lin FY, Philips JB 3rd, Azimi PH, Weisman LE, Clark P, Rhoads GG, Regan J, Concepcion NF, Frasch CE, Troendle J, Brenner RA, Gray BM, Bhushan R, Fitzgerald G, Moyer P, Clemens JD.

J Infect Dis. 2001 Oct 15;184(8):1022-8. Epub 2001 Aug 31.

PMID:
11574917
34.
35.

Immunogenicity in mice of pneumococcal glycoconjugate vaccines using pneumococcal protein carriers.

Lee CJ, Wang TR, Frasch CE.

Vaccine. 2001 Apr 30;19(23-24):3216-25.

PMID:
11312018
37.

Development of natural immunity to Neisseria meningitidis.

Pollard AJ, Frasch C.

Vaccine. 2001 Jan 8;19(11-12):1327-46. Review.

PMID:
11163654
38.

Outer membrane protein vesicle vaccines for meningococcal disease.

Frasch CE, van Alphen L, Holst J, Poolman JT, Rosenqvist E.

Methods Mol Med. 2001;66:81-107. doi: 10.1385/1-59259-148-5:81.

PMID:
21336749
39.

Genetic and immunologic characterization of a novel serotype 4, 15 strain of Neisseria meningitidis.

Bash MC, Lynn F, Concepcion NF, Tappero JW, Carlone GM, Frasch CE.

FEMS Immunol Med Microbiol. 2000 Nov;29(3):169-76.

40.

An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study.

Plikaytis BD, Goldblatt D, Frasch CE, Blondeau C, Bybel MJ, Giebink GS, Jonsdottir I, Käyhty H, Konradsen HB, Madore DV, Nahm MH, Schulman CA, Holder PF, Lezhava T, Elie CM, Carlone GM.

J Clin Microbiol. 2000 Jun;38(6):2043-50.

41.

Specificity of human antibodies reactive with pneumococcal C polysaccharide.

Frasch CE, Concepcion NF.

Infect Immun. 2000 Apr;68(4):2333-7.

43.

Inhibition enzyme-linked immunosorbent assay for serotyping of group B streptococcal isolates.

Arakere G, Flores AE, Ferrieri P, Frasch CE.

J Clin Microbiol. 1999 Aug;37(8):2564-7.

44.

Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic.

Yu X, Sun Y, Frasch C, Concepcion N, Nahm MH.

Clin Diagn Lab Immunol. 1999 Jul;6(4):519-24.

45.
46.

Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature.

Sacchi CT, Lemos AP, Brandt ME, Whitney AM, Melles CE, Solari CA, Frasch CE, Mayer LW.

Clin Diagn Lab Immunol. 1998 Nov;5(6):845-55.

47.

The use of oligonucleotide probes for meningococcal serotype characterization.

Sacchi CT, de Lemos AP, Whitney AM, Melles CE, Solari CA, Frasch CE, Mayer LW.

Rev Inst Med Trop Sao Paulo. 1998 Mar-Apr;40(2):113-7.

PMID:
9755566
48.

Meningococcal disease caused by Neisseria meningitidis serogroup B serotype 4 in São Paulo, Brazil, 1990 to 1996.

Sacchi CT, de Lemos AP, Camargo MC, Whitney AM, Melles CE, Solari CA, Frasch CE, Mayer LW.

Rev Inst Med Trop Sao Paulo. 1998 Mar-Apr;40(2):65-70.

PMID:
9755558
49.

The immunogenicity of Haemophilus influenzae type b conjugate vaccines in children born to human immunodeficiency virus-infected women. Women and Infants Transmission Study Group.

Read JS, Frasch CE, Rich K, Fitzgerald GA, Clemens JD, Pitt J, Pelton SI, Hanson IC, Handelsman E, Diaz C, Fowler MG.

Pediatr Infect Dis J. 1998 May;17(5):391-7.

PMID:
9613652
50.

Correlation between serological and sequencing analyses of the PorB outer membrane protein in the Neisseria meningitidis serotyping system.

Sacchi CT, Lemos AP, Whitney AM, Solari CA, Brandt ME, Melles CE, Frasch CE, Mayer LW.

Clin Diagn Lab Immunol. 1998 May;5(3):348-54.

Supplemental Content

Loading ...
Support Center